GoodRx Holdings (GDRX) Liabilities and Shareholders Equity (2019 - 2026)

GoodRx Holdings (GDRX) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $2.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 56.05% year-over-year to $2.0 billion; the trailing twelve-month figure through Mar 2026 stood at $6.1 billion (up 10.08% YoY), and the FY2025 full-year result was $1.4 billion, up 1.15% from the prior year.
• Liabilities and Shareholders Equity climbed to $2.0 billion in Q1 2026, from $1.4 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.0 billion in Q1 2026 to a low of $1.3 billion in Q1 2025.
• A 5-year average of $1.5 billion and a median of $1.5 billion in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity fell 20.68% in 2024 and soared 56.05% in 2026, its largest moves.
• Tracing GDRX's Liabilities and Shareholders Equity over 5 years: stood at $1.6 billion in 2022, then fell by 0.99% to $1.6 billion in 2023, then fell by 12.63% to $1.4 billion in 2024, then increased by 1.15% to $1.4 billion in 2025, then jumped by 43.96% to $2.0 billion in 2026.
• Business Quant data shows GDRX's Liabilities and Shareholders Equity at $2.0 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.3 billion in Q3 2025.